LY3039478是一种有效的Notch抑制剂,IC50为0.41 nM。
理化数据
分子量 |
464.44 |
化学式 |
C22H23F3N4O4 |
CAS号 |
1421438-81-4 |
稳定性 |
3 years -20°C powder |
溶解性
DMSO |
92 mg/mL (198.08 mM) |
Ethanol |
71 mg/mL (152.87 mM) |
Water |
Insoluble |
生物活性
产品描述 |
LY3039478是一种有效的Notch抑制剂,IC50为0.41 nM。 |
||
靶点 |
|
||
体外研究 |
LY3039478 is a novel small molecule that is an exquisitely potent inhibitor of Notch-1 intracellular domain (N1ICD) cleavage with an IC50 of ∼1nM in most of the tumor cell lines tested. LY3039478 also potently inhibits mutant Notch receptor activity. Treatment with a gamma secretase inhibitor, LY3039478, significantly inhibited the growth of 2 CCRCC(Clear cell renal cell carcinoma) cell lines in a concentration dependent manner. LY3039478 treatment also led to decreased expression of Myc and Cyclin A1, two genes that were part of the NOTCH driven proliferative signature in murine and human model systems. LY3039478 treatment also led to G0/G1 cell cycle arrest in CCRCC cells。 |
||
体内研究 |
In mice, its oral bioavalability(%F) is 65%, clearance(CL)=41 mL/min/kg, VDss = 3.8 L/kg. In Rats, its oral bioavalability(%F) is 65%, CL=98 mL/min/kg, VDss=4.9 L/kg. In Dogs, its oral bioavalability (%F) is 67%, CL=3.8 mL/min/kg, VDss=1.4 L/kg. In a xenograft tumor model, LY3039478 inhibited N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. The inhibition of Notch cleavage also resulted in the induction of apoptosis in a Notch-dependent xenograft model. In immunodeficient NSG mice xenografted with 769-P CCRCC cells, LY3039478 treatment resulted in significantly increased survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC。 |
实验操作
细胞实验: |
|
动物实验: |
|